NK Cells + Cetuximab for Colorectal Cancer Metastasis

This trial explores a new treatment approach for patients with colorectal cancer that has spread to the abdomen. Researchers aim to determine the safest and most effective dose of two treatments: NK cells (natural killer cells) and cetuximab, administered both intravenously and directly into the abdominal cavity. Participants with colorectal cancer primarily affecting the abdomen, who have not found success with standard treatments, might be suitable candidates. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the opportunity to be among the first to receive this innovative therapy.

The trial requires participants to be at least 4 weeks from their last dose of systemic chemotherapy, or 6 weeks if it included Bevacizumab, before starting the study. It does not specify other medications, so you should discuss your current medications with the study team to see if any adjustments are needed.

Research shows that using TROP2-CAR-NK cells with cetuximab might be safe and manageable for people with colorectal cancer. Although detailed safety information for this specific combination is not yet available, similar studies on CAR-NK cell therapy in cancer have shown encouraging results. Patients generally tolerated these treatments well. Additionally, cetuximab has FDA approval for other uses, indicating its relative safety when used properly. It is important to note that this treatment is currently in early clinical trials, so researchers are still learning about its safety and possible side effects.¹²³⁴⁵

Researchers are excited about the NK Cells + Cetuximab treatment for colorectal cancer metastasis because it uses a novel approach of TROP2-directed CAR-NK cells. Unlike the standard chemotherapy or targeted therapy options, this treatment combines a cellular therapy with an antibody, cetuximab, to potentially enhance the immune system's ability to target and kill cancer cells. Additionally, the dual administration method—both intravenously and directly into the abdominal cavity—aims to more effectively reach cancer cells that have spread to the peritoneum, offering a promising new strategy for managing this challenging condition.

Research has shown that TROP2 is a protein often found in large amounts in various solid tumors, including colorectal cancer, making it a good target for treatments. In this trial, participants will receive TROP2-directed CAR-NK cells, which have shown promise in studies due to their natural ability to kill tumor cells. The trial includes two arms: a Dose Escalation arm to find the highest safe dose of NK cells administered intravenously and intraperitoneally with cetuximab, and a Dose Expansion arm to evaluate the effectiveness of the recommended dose. When combined with cetuximab, a drug that targets cancer cells, this therapy has been found to be potentially safe and manageable for patients with small amounts of remaining colorectal cancer. Early findings suggest that this combination might help control the disease by reducing tumor growth and spread. While more research is needed, these initial results are encouraging for patients with advanced colorectal cancer.²³⁴⁶⁷